EcoDrugPlus

Voltage-Dependent L-Type Calcium Channel Subunit Beta-3

Ensembl ID : ENSOKIG00005015126
Gene Symbol: LOC109908510
3 Cross references
187 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Beta-4-Like

Ensembl ID : ENSOKIG00005007636
Gene Symbol: LOC109868051
3 Cross references
198 Possible Orthologues:

Voltage-Dependent T-Type Calcium Channel Subunit Alpha-1h

Ensembl ID : ENSOKIG00005030097
Gene Symbol: LOC109884421
2 Cross references
205 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-1 Subunit

Ensembl ID : ENSOKIG00005019584
Gene Symbol: LOC109865839
3 Cross references
188 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-1 Subunit-Like

Ensembl ID : ENSOKIG00005047641
Gene Symbol: LOC109889573
3 Cross references
188 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-3 Subunit-Like

Ensembl ID : ENSOKIG00005044433
Gene Symbol: LOC116360820
2 Cross references
189 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-3 Subunit-Like

Ensembl ID : ENSOKIG00005027593
Gene Symbol: LOC116373136
2 Cross references
189 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSOKIG00005015608
Gene Symbol: LOC109903657
3 Cross references
161 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSOKIG00005040182
Gene Symbol: LOC109907561
3 Cross references
160 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSOKIG00005046335
Gene Symbol: LOC116359842
3 Cross references
189 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-6 Subunit

Ensembl ID : ENSOKIG00005015621
Gene Symbol: LOC109903666
3 Cross references
176 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-6 Subunit-Like

Ensembl ID : ENSOKIG00005040166
Gene Symbol: LOC109908459
3 Cross references
175 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).